Fractyl Health reported a net loss of $30.5 million for the first nine months of 2026, a significant improvement from the $97.2 million loss in the prior year period, primarily driven by a $29.1 million gain from the change in fair value of warrant liabilities. The company implemented a strategic reprioritization in October 2026, including a workforce reduction, to extend its financial runway as cash and cash equivalents decreased to $31.5 million from $81.5 million at year-end 2025.
Pershing Square SPARC Holdings, Ltd. reported a net loss of $1.86 million for the quarter ended September 30, 2026, primarily driven by legal fees and a $1.77 million change in the fair value of Sponsor Warrants liability. The company remains a shell company focused on identifying a business combination, with $19.26 million in total cash and cash equivalents as of the period end.
Azora Therapeutics, Inc. (formerly Adial Pharmaceuticals) reported a significant net loss of $118.6 million for the nine months ended September 30, 2026, primarily driven by a $46.2 million charge for acquired in-process R&D and a $48.8 million change in the fair value of milestone warrant rights. Following its acquisition of Legacy Azora in June 2026, the company's cash position increased to $22.0 million, supported by $26.8 million in proceeds from a private placement of pre-funded warrants.
Brightline Interactive, Inc. reported a net loss of $1.44 million for the quarter ended September 30, 2026, compared to a $1.03 million loss in the prior year period. The company underwent a major restructuring in mid-2026, divesting most subsidiaries to focus on its SpatialCore platform, and has issued a going concern warning due to recurring losses and an accumulated deficit of $83.66 million.
For the nine months ended September 30, 2026, the Partnership reported net income of $29,303, a significant decrease from $236,353 in the prior year period, primarily due to a $200,237 gain on real estate sales in 2025. The Managing General Partner has decided to begin the final liquidation process of the Partnership by disposing of its remaining assets.
BC Partners Lending Corp reported total investment income of $16.9 million for the nine months ended September 30, 2026, compared to $14.2 million in the prior year period. The company experienced a net decrease in net assets resulting from operations of $1.8 million for the nine-month period, primarily driven by $8.5 million in net realized and unrealized losses which offset $6.7 million in net investment income.
Fractyl Health reported Q3 2026 financial results and announced a major strategic pivot to focus on its Revita program, including a 45% workforce reduction and the discontinuation of internal Rejuva development. The company reported positive six-month pivotal data from its REMAIN-1 trial and plans to submit an FDA De Novo marketing application in late Q4 2026.
Term
Q3 2026
“There are approximately 1 million Americans discontinuing GLP-1s each month, and these individuals are at high risk of weight and metabolic rebound. In this context, we believe the positive pivotal results from REMAIN-1 represent a defining moment for Fractyl. In the most rigorous stress test we could conceive, a single Revita procedure met its six-month co-primary endpoint with high statistical significance.”
Harith Rajagopalan, M.D., Ph.D., Co-Founder, President and Chief Executive Officer
“Armed with positive data, we have focused the Company around Revita’s post-GLP-1 weight maintenance opportunity. We expect the capital we have today to be sufficient to fund our planned De Novo submission and upcoming 12-month pivotal data and. Our goal is for Revita to potentially establish an entirely new therapeutic category of post-GLP-1 weight maintenance by aiming to reverse years of diet-induced damage to the gut.”
Harith Rajagopalan, M.D., Ph.D., Co-Founder, President and Chief Executive Officer
Candel Therapeutics reported third quarter 2026 financial results, ending the period with $203.1 million in cash which is expected to fund operations into Q2 2028. The company updated its regulatory timeline, now planning to submit a Biologics License Application (BLA) for aglatimagene in prostate cancer in mid-2027 following assay refinement. Recent clinical progress included three poster presentations at the SITC 41st Annual Meeting showcasing data across its prostate, lung, and glioma programs.
Term
Q3 2026
“During the quarter we continued to execute well and make significant progress across the business, as we build the foundation to potentially become a commercial-stage biopharma company.”
Paul Peter Tak, M.D., Ph.D., FMedSci, President and CEO
“On the clinical side, we were honored to have had three posters accepted for presentation at SITC, featuring data on aglatimagene in localized prostate cancer and non-small cell lung cancer, and linoserpaturev in recurrent high-grade glioma. Together, the new biomarker data provide mechanistic support for the systemic effect and long-term clinical outcomes observed in our phase 3 trial of aglatimagene in patients with intermediate- to high-risk localized prostate cancer.”
Paul Peter Tak, M.D., Ph.D., FMedSci, President and CEO
BioStem Technologies reported Q3 2026 financial results, highlighting sequential hospital revenue growth to $6.8 million and increased customer penetration. The company raised its full-year 2026 revenue guidance and is finalizing a cost reduction plan to reduce annualized cash operating expenses by $10-$12 million.
Term
Q3 2026
“We grew hospital revenue again this quarter, and importantly, are doing so by adding new accounts and increasing penetration with existing customers. The number of customers buying two or more of our product lines grew 14% from the second quarter. We also completed the final step of our commercial infrastructure build-out, and with in-house production of Neox and Clarix expected to begin in the first half of 2027, we are on track to become a fully vertically integrated company with those product lines.”
Jason Matuszewski, Chair and CEO of BioStem
“With these foundations in place, we are focused on strengthening the balance sheet, raising our gross margin, reducing operating expenses and narrowing our adjusted EBITDA loss as we work toward breakeven.”
Hour Loop reported Q3 2026 financial results with net revenues of $32.1 million, a 4% decrease year-over-year, and net income of $0.4 million. The company narrowed its full-year 2026 guidance and highlighted its transition to an AI-first operating model to drive efficiency in purchasing and customer service.
Term
Q3 2026
“Through the first nine months of 2026, Hour Loop grew net revenues 11% and earned $2.3 million in net income, and we stayed profitable through a tougher third quarter. We made a deliberate choice to protect our margins rather than chase low-quality sales, and we believe that discipline puts us in a strong position as we head into the holiday season, the most important time of our year.”
Sam Lai, Chief Executive Officer and Interim Chief Financial Officer
“We are building an AI-first company, and AI is already changing how we work every day. AI agents now support core parts of our operations – purchasing and replenishment, advertising, pricing, inbound shipments, inventory reconciliation, customer service and compliance.”
Sam Lai, Chief Executive Officer and Interim Chief Financial Officer
Talphera reported a Q3 2026 net loss of $4.0 million and ended the quarter with $14.2 million in cash and investments. The company has submitted a briefing document to the FDA requesting to close enrollment for its pivotal NEPHRO CRRT study by year-end 2026, citing that current enrollment provides over 80% statistical power for the primary endpoint.
“We believe nafamostat has the potential to address an important unmet need as a regional anticoagulant for critically ill patients undergoing CRRT. Our updated market research, including physician feedback on nafamostat compared with currently used products, supports its potential adoption in CRRT and an increased peak sales estimate of more than $200 million.”
Vince Angotti, CEO of Talphera
“To date, we have enrolled more than 75% of the planned 70 patients. To support our goal of completing the study this year, we have submitted a briefing document to the FDA seeking feedback on closing enrollment as of December 31, 2026, even if fewer than the targeted 70 patients are enrolled. While the study remains blinded and open for enrollment, we believe the current enrollment is sufficient to support a PMA filing as it has over 80% statistical power for the primary endpoint.”
Beeline Holdings reported Q3 2026 revenue of $3.0 million, a 30% year-over-year increase, while narrowing its net loss to $3.8 million. The company highlighted a shift toward higher-margin mortgage products and announced that definitive agreements for its acquisition of TYTL are expected to be signed within days. To reduce dilution, the CEO has agreed to forfeit 3 million of the 9 million merger shares he is slated to receive upon the closing of the TYTL deal.
Term
Q3 2026
“Despite challenging market conditions, our third quarter reflects measurable progress in the core business. Revenue grew 30% year-over-year while operating expenses declined sequentially. We are focusing on higher-margin mortgage products, improved conversion and AI-enabled efficiency. We remain disciplined about liquidity and cost reduction as we work toward a more scalable operating model.”
Assembly Biosciences reported Q3 2026 financial results and announced the receipt of a $75 million collaboration extension fee from Gilead Sciences, extending its cash runway into 2029. The company also exercised its option to share 40% of U.S. development costs and profits for the HSV helicase primase inhibitor program and initiated a Phase 2 study for ABI-6250 in chronic hepatitis delta virus.
Counterparty
Gilead Sciences, Inc.
“This quarter, we rapidly advanced our liver disease program by initiating the Phase 2 study of ABI-6250 in chronic hepatitis delta virus and preparing for our Phase 2 study in cholestatic liver diseases, which we expect to begin in the first quarter next year. Alongside that progress, we elected to share U.S. costs and profits for the HSV helicase primase inhibitor program under our collaboration with Gilead, a decision we believe represents a significant opportunity to build long-term value. With a strong financial position, we look forward to the continued expansion of our pipeline and advancement of the herpesvirus and liver disease programs through their respective Phase 2 studies.”
Jason Okazaki, chief executive officer and president of Assembly Bio
ENB Financial Corp reported net income of $16.6 million for the nine months ended September 30, 2026, a slight increase from $16.0 million in the prior year period. Total assets grew to $2.4 billion, driven by a significant increase in net loans to $1.69 billion, while the company also recorded a $3.7 million expense related to merger and conversion activities.
Universal Logistics Holdings reported a net income of $18.1 million for the third quarter of 2026, a significant recovery from a net loss of $117.9 million in the same period of 2025. The prior year's results were heavily impacted by a $124.4 million impairment expense, while the current period benefited from a $48.4 million gain on the disposal of property and equipment.
Interlink Electronics reported Q3 2026 revenue of $3.06 million, a 3.4% increase year-over-year, driven by higher shipments of force-sensing and gas-sensor products. The company also announced the expansion of its R&D and manufacturing footprint in the UK and Scotland to support smart textiles and medical applications. Management expects a previously announced transformative acquisition to close in Q4 2026, projecting pro forma 2026 revenue of $50 million.
Term
Q3 2026
“We continue to invest in our business and take the necessary steps to drive long-term growth. We feel confident that our existing technologies and capabilities, coupled with adding additional sales and marketing resources, will position us for organic growth in the coming years.”
HeartBeam, Inc. reported a net loss of $12.7 million for the nine months ended September 30, 2026, compared to $15.7 million in the prior year period. The company remains pre-revenue and issued a going concern warning, stating that its $6.1 million in cash is insufficient to fund operations for the next twelve months.
HawkEye 360 reported Q3 2026 revenue of $59.3 million, an 84% increase year-over-year, driven by strong international growth. The company raised its full-year 2026 revenue guidance to $225-$227 million and highlighted a record backlog of $300.3 million.
Term
Q3 2026
“I am pleased with our third quarter results as we continue to see strong momentum for signals intelligence data and analytics. Importantly, growth on the international side of our business continues to gain significant traction, highlighted by revenue increasing 76% year-over-year to $23.3 million.”
John Serafini, Chief Executive Officer
“More recently, we reached another milestone in our next phase of constellation expansion with the launches of Clusters 15 and 16 in October. Following deployment, our space operations team successfully established communications with all six satellites across both clusters.”
Erasca, Inc. reported a significant increase in net loss to $278.9 million for the nine months ended September 30, 2026, primarily driven by a $150.0 million in-process research and development charge. Despite the loss, the company strengthened its balance sheet through underwritten offerings, ending the period with $947.8 million in cash, cash equivalents, and marketable securities.
NorthStar Earth & Space Enterprises, Inc. reported a net income of $2.36 million for the nine months ended September 30, 2026, primarily driven by $5.91 million in interest income from its Trust Account. The company, a former SPAC, consummated its business combination on October 1, 2026, and reported a shareholders' deficit of $11.5 million as of the quarter-end.
Cerebras Systems reported record Q3 2026 GAAP revenue of $210.8 million, up 55% year-over-year, driven by a 265% surge in cloud services revenue. The company raised its full-year 2026 core revenue outlook to a range of $940 million to $960 million and announced strategic cloud partnerships with Oracle and a top-three hyperscaler.
Term
Q3 2026
“Cerebras’ technology remains the undisputed champion of speed. We’re giving customers more ways to access our technology and scale with us be it through direct system sales, Cerebras Cloud or third-party cloud providers. I’m proud of our team for delivering the performance and speed customers need to build entirely new applications and expand what AI can do. That progress energizes us to do even more as we push the limits of innovation and expect to triple revenue in 2027.”
Andrew Feldman, co-founder and CEO of Cerebras
“We exceeded our guidance across the board for the third quarter in a row and delivered sequential improvements on all core financial metrics. We won new marquee customers, including hyperscalers, neoclouds and large enterprises. And we saw our pipeline for high-speed AI inference increase by more than 10x in the quarter.”
IZEA Worldwide reported Q3 2026 revenue of $6.2 million, a 23% decrease year-over-year, despite a 94% surge in Managed Services bookings to $7.0 million. The company narrowed its net loss to $0.4 million and provided Q4 2026 revenue guidance of $7.5 million to $8.1 million, signaling a return to growth.
Term
Q3 2026
“Our third quarter results demonstrate progress in our enterprise-focused transformation. With bookings up 94% and double-digit growth across our largest clients, this reflects the performance we are working to replicate across the business. We enter Q4 with strong momentum and confidence in achieving our revenue guidance. With $46.4 million in cash and no long-term debt, we are continuing to pursue strategic acquisitions to accelerate growth, expand our capabilities, and strengthen our competitive position in the creator economy.”
Enhanced Group Inc. reported Q3 2026 financial results with revenue of $3.3 million and a net loss of $13.5 million. The company highlighted its pending acquisition of a 77% stake in DEAG Deutsche Entertainment AG, which is expected to significantly scale the combined group's 2027 revenue to approximately $670 million. Operational milestones included the launch of the AI-powered 'Enhanced OS' platform and the completion of the 'Enhanced Breakers 1' event.
Mannatech reported Q3 2026 net sales of $24.9 million, a 14.6% decrease year-over-year on a constant dollar basis. While net income rose to $8.9 million ($4.61 per diluted share), this was driven by a one-time $10.9 million non-cash income tax benefit rather than operating performance, as the company recorded a pre-tax loss of $2.0 million.
CV Sciences reported third quarter 2026 revenue of $3.0 million, a 7% decrease year-over-year due to restrictive regulations and lower sales volumes. Despite the revenue decline, the company achieved positive adjusted EBITDA of $32,000 and expanded gross margins to 50.0% through cost discipline and operational efficiency.
Term
Q3 2026
“Our third quarter results demonstrate continued progress in strengthening the operating performance of our business despite ongoing regulatory challenges and pressure on revenue. We expanded gross margins to 50.0%, reduced operating expenses by 11.6% year over year, and achieved positive adjusted EBITDA of $32,000, compared to adjusted EBITDA losses in both the prior-year quarter and the second quarter of 2026.”
Joseph Dowling, Chief Executive Officer
“Looking ahead, we remain focused on strengthening our established brands, expanding our presence in broader science-based wellness categories, maintaining disciplined capital allocation, and pursuing strategic opportunities that support sustainable growth and long-term shareholder value.”
Lifeway Foods reported record quarterly net sales of $67.8 million for Q3 2026, marking its 28th consecutive quarter of year-over-year growth. While sales grew 18.6%, net income fell to $0.3 million due to elevated input costs for milk, packaging, and transportation. The company expects gross margin expansion in 2027 driven by planned price increases and capacity investments at its Waukesha facility.
Term
Q3 2026
“Lifeway delivered another record breaking quarter with net sales of $67.8 million, extending our streak of topline growth to 28 consecutive quarters. The consistent, volume-led growth we are seeing for our authentic Lifeway Kefir and Lifeway Farmer Cheese is extraordinary, reflecting the deep trust we have established with our growing consumer base and the ongoing commitment of our retailer partners.”
Julie Smolyansky, President and Chief Executive Officer of Lifeway Foods
“Profitability this quarter continued to reflect an elevated input cost environment, and while we expect the cost pressure to persist in the fourth quarter, our outlook for 2027 has not changed. We expect the planned price increases across our portfolio to take effect with distributors and retailers on a rolling basis through the end of the year and into the first quarter of 2027.”
Julie Smolyansky, President and Chief Executive Officer of Lifeway Foods
Interlink Electronics reported a net loss of $0.32 million for the quarter ended September 30, 2026, compared to a $0.34 million loss in the prior year period. While revenue increased to $3.06 million from $2.96 million, the company faced higher costs of revenue and continued operating losses, resulting in a year-to-date net loss of $0.41 million.
Nuwellis reported Q3 2026 financial results with net sales of $2.2 million and a 24% improvement in operating loss to $2.1 million. The company highlighted significant gross margin expansion to 69.5% and an 88% year-to-date increase in Aquadex console unit sales, which builds the installed base for future recurring revenue.
Term
Q3 2026
“We have made meaningful progress in strengthening Nuwellis both commercially and financially. Year to date, console unit sales have nearly doubled, expanding our installed base and creating a larger opportunity to grow recurring circuit revenue. Although our third quarter faced a tough comparison against the prior-year period when we fulfilled a significant backorder, the underlying momentum in our business remains strong, as evidenced by the growth in our pediatric segment.”
Mike McCormick, Nuwellis President and Chief Executive
For the quarter ended September 30, 2026, VirTra reported net sales of $7.6 million, a significant increase from $5.3 million in the prior year period, resulting in a net income of $2.16 million. However, for the nine-month period, net sales decreased to $16.8 million compared to $19.5 million in 2025, reflecting fluctuations in contract timing.
For the nine months ended September 30, 2026, Mannatech reported net sales of $76.4 million and a net income of $10.9 million, a significant recovery from a $3.9 million net loss in the prior year period. This improvement was primarily driven by a $10.5 million income tax benefit and reduced operating expenses, despite a decline in overall net sales.